Modeling hepatic fibrosis in TP53 knockout iPSC ‐derived human liver organoids
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Mustafa Karabicici und 8 weiteren Autor:innen. Beteiligte Einrichtung: Izmir Biomedicine and Genome Center (IBG), Dokuz Eylul University Health Campus, Izmir, Turkey. Hauptthemen laut MEDLINE: Organoids, Liver Cirrhosis, Tumor Suppressor Protein p53, Induced Pluripotent Stem Cells. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.
Abstract (Originalsprache)
Hepatic fibrogenesis is characterized by the excessive accumulation of extracellular matrix proteins, ultimately predisposing to hepatocarcinogenesis. The lack of reliable models that faithfully recapitulate early stage fibrogenesis is one of the main limitations in identifying translationally relevant therapeutics. Here, we establish a model using CRISPR/Cas9‐mediated TP53 knockout iPSC (endoderm)‐derived human hepatic organoids (eHEPOs) to mimic human liver fibrosis. Transcriptomic profiling of TP53KO‐eHEPOs revealed enrichment of pathways associated with inflammation, ECM remodeling, and fibrosis, with notable alterations in pivotal fibrotic regulators. We also find increased expression of myofibroblasts and fibrosis markers (PDGFRB, COL1A1, COL3A1, COL11A1) and early liver cancer markers (GPC3 and MUC1). Histological analysis confirmed advanced fibrotic hallmarks and exposure to an exogenous profibrotic environment (pf‐ME) further enhanced these fibrotic phenotypes. This model provides a valuable platform for exploring the role of key driver genes, such as TP53, in the initiation and progression of fibrosis, enabling the study of hepatic progenitor cell transformation across diverse microenvironmental contexts. As such, it holds the potential for advancing early stage drug discovery and the identification of novel therapeutic targets for the treatment of liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Izmir Biomedicine and Genome Center (IBG), Dokuz Eylul University Health Campus, Izmir, Turkey.
- Izmir International Biomedicine and Genome Institute (IBG-Izmir), Dokuz Eylul University, Izmir, Turkey.
- Department of Pathology, Izmir Bozyaka Education and Research Hospital, University of Health Sciences, Turkey.
- Department of Medical Biology and Genetics, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
ORCID-Profile: Mustafa Karabicici, Serif Senturk, Esra Erdal
Förderung
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Zitieren
APA
Karabicici, M., Akbari, S., Caliskan, C., Celiker, C., Oz, O., Binokay, L., Karakulah, G., Senturk, S., & Erdal, E. (2025). Modeling hepatic fibrosis in TP53 knockout iPSC ‐derived human liver organoids. Molecular Oncology. https://doi.org/10.1002/1878-0261.70119
Vancouver
Karabicici M, Akbari S, Caliskan C, Celiker C, Oz O, Binokay L, et al. Modeling hepatic fibrosis in TP53 knockout iPSC ‐derived human liver organoids. Molecular Oncology. 2025. doi:10.1002/1878-0261.70119
BibTeX
@article{Karabicici2025,
author = {Karabicici, Mustafa and Akbari, Soheil and Caliskan, Ceyda and Celiker, Canan and Oz, Ozden and Binokay, Leman and Karakulah, Gökhan and Senturk, Serif and Erdal, Esra},
title = {Modeling hepatic fibrosis in TP53 knockout iPSC ‐derived human liver organoids},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70119}
}
EUVIMED